Literature DB >> 1572960

Proposed interpretive criteria and quality control parameters for ofloxacin susceptibility testing of Neisseria gonorrhoeae.

P C Fuchs1, A L Barry, C Baker, P R Murray, J A Washington.   

Abstract

A multilaboratory study designed to determine the in vitro susceptibility criteria and quality control parameters for ofloxacin against Neisseria gonorrhoeae was conducted according to the guidelines of the National Committee for Clinical Laboratory Standards. Proposed susceptibility breakpoints are MICs of less than or equal to 0.25 microgram/ml for the agar dilution test and greater than or equal to 31 mm for the disk diffusion test. A category for resistance could not be defined. Proposed acceptable quality control MICs for N. gonorrhoeae ATCC 49226 and Staphylococcus aureus ATCC 29213 range from 0.004 to 0.03 microgram/ml and 0.25 to 1.0 microgram/ml, respectively. With 5-micrograms ofloxacin disks, acceptable inhibitory zone diameters for S. aureus ATCC 25923 and the N. gonorrhoeae control strains range from 22 to 27 mm and 43 to 51 mm, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1572960      PMCID: PMC265209          DOI: 10.1128/jcm.30.4.1024-1026.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains.

Authors:  J M Covino; M Cummings; B Smith; S Benes; K Draft; W M McCormack
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

2.  Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection.

Authors:  J R Black; J M Long; B E Zwickl; B S Ray; M S Verdon; S Wetherby; E W Hook; H H Handsfield
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

4.  Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease.

Authors:  B E Batteiger; R B Jones; A White
Journal:  Am J Med       Date:  1989-12-29       Impact factor: 4.965

5.  Single-dose efficacy of ofloxacin in uncomplicated gonorrhea.

Authors:  F B Lutz
Journal:  Am J Med       Date:  1989-12-29       Impact factor: 4.965

6.  Clinical experience with ofloxacin in sexually transmitted disease.

Authors:  F N Judson; B S Beals; K J Tack
Journal:  Infection       Date:  1986       Impact factor: 3.553

7.  The in vitro activity of norfloxacin, ofloxacin and ciprofloxacin and other antibiotics in current use against Neisseria gonorrhoeae.

Authors:  K Melby; A Faegri
Journal:  APMIS       Date:  1989-04       Impact factor: 3.205

  7 in total
  3 in total

1.  Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.

Authors:  A L Barry; P C Fuchs; S D Allen; J H Jorgensen; F C Tenover; P R Murray; D J Hardy; C N Baker
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

2.  Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.

Authors:  J S Knapp; J A Hale; S W Neal; K Wintersheid; R J Rice; W L Whittington
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 3.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.

Authors:  T Fekete
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.